

**BioPharmaReporter**

# **Editorial Calendar**

## **2024 & 2025**

**WilliamReed.**

# Yearly Overview 2024

JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
<div>24</div> Special Edition: Cell & Gene Therapy	<div>21</div> Special Edition: Drug Delivery (BPR & OSP) <div>28</div> Editorial Webinar: Innovations In Drug Delivery	<div>27</div> Special Edition: Obesity Drugs	<div>17</div> Pre-Show: CPHI North America <div>18</div> Editorial Webinar: Cell & Gene Therapy	<div>15</div> Pre-Show: Bio International <div>29</div> Pre-Show: ACHEMA	<div>05</div> Pre-Show: DIA Annual Meeting
JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
<div>24</div> Special Edition: Trends In Biosimilars	<div>21</div> Special Edition: Delivery Systems For Biologics	<div>18</div> Special Edition: Manufacturing	<div>02</div> Pre-Show: CPHI <div>16</div> Pre-Show: AAPS Pharmsci360	<div>20</div> Special Edition: Patient Centricity	<div>11</div> Special Edition: The Path To A Biologics License Application



SPECIAL EDITION



PRE-SHOW



EDITORIAL WEBINAR

# Yearly Overview 2025

JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
<div>15</div> <div>Special Edition: Emerging Biopharma Hubs</div>	<div>12</div> <div>Special Edition: Bioprocessing 4.0</div>	<div>12</div> <div>Special Edition: Taking Biologics Through The Clinic</div>			
JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER

SPECIAL EDITION

PRE-SHOW

EDITORIAL WEBINAR

# 2024

JANUARY

24

## SPECIAL EDITION: **CELL & GENE THERAPY**

The cell and gene therapy sector is one of the most promising areas of the biopharmaceutical industry, with industry changing approvals of therapies occurring at a rapid pace. One of the challenges for such therapies, however, remains the ability to manufacture the products efficiently and at a reasonable cost. In this feature round-up, Bio-Pharma Reporter will explore some of the ways the industry is improving production.

FEBRUARY

21

## SPECIAL EDITION: **DRUG DELIVERY (BPR & OSP)**

TBC

28

## EDITORIAL WEBINAR: **INNOVATIONS IN DRUG DELIVERY (BPR & OSP)**

Innovations in drug delivery never stop and constant progress continues way past the oral route with the development of implants, patches, syringes as well as solutions for transdermal, topical, and oral drug delivery systems that target diseases, provide pain management, address skin conditions, and are used as gastrointestinal aids.

These varying solutions for drug delivery applications are in higher demand than ever because of the aging population, an increase in chronic disease, and patients' increased access to safe and convenient care. This webinar will hear from experts and what their thoughts are on the ever-evolving market and any successes or learning they would like to share.

MARCH

27

## SPECIAL EDITION: **OBESITY DRUGS**

Obesity drugs are taking the market by storm. From Ozempic to Wegovy, the market is expected to reach \$54 billion by 2030 according to Morgan Stanley. Bio-Pharma Reporter investigates whether the treatments will become a new blockbuster pharma category and outlines the main players.



SPECIAL EDITION



PRE-SHOW



EDITORIAL WEBINAR

APRIL	
17	PRE-SHOW: <b>CPHI NORTH AMERICA</b> PRE-SHOW
18	EDITORIAL WEBINAR: <b>CELL &amp; GENE THERAPY</b> TBC
MAY	
15	PRE-SHOW: <b>BIO INTERNATIONAL</b> PRE-SHOW
29	PRE-SHOW: <b>ACHEMA</b> PRE-SHOW
JUNE	
05	PRE-SHOW: <b>DIA ANNUAL MEETING</b> PRE-SHOW

 SPECIAL EDITION

 PRE-SHOW

 EDITORIAL WEBINAR

JULY

24

### SPECIAL EDITION: **TRENDS IN BIOSIMILARS**

Biosimilars are gaining popularity worldwide, with half of projected global sales for the segment, over the next five years, expected to come from emerging markets. While these drugs are in great demand, manufacturers of biosimilars face a number of hurdles, ones that can threaten their capacity to produce such drugs in a cost-effective manner, such as producers of the reference products undercutting price by streamlining their workflows. We will get an up to date perspective on that challenge and others in this special newsletter.

AUGUST

21

### SPECIAL EDITION: **DELIVERY SYSTEMS FOR BIOLOGICS**

Scientists today are looking to develop the next generation of drug delivery technologies, hoping to ensure novel treatments can effectively reach patients by optimizing the design, properties, analysis, formulation and delivery of new medicines and therapies. Our focus will be on innovations in gene therapy drug delivery, and on oral biologics, looking at the work done to date on creating safe and effective oral formulations of therapies traditionally limited to injections, among other exciting developments in this field.

SEPTEMBER

18

### SPECIAL EDITION: **MANUFACTURING**

The global spotlight has been trained on vaccine manufacture in the past two years like never before, following on from the COVID-19 pandemic. The manufacture of vaccines is a complicated and costly task, but a raft of new modalities are on the horizon, and the technology has advanced in recent times: the mRNA platform offers promise in terms of speed and agility in vaccine production.



SPECIAL EDITION



PRE-SHOW



EDITORIAL WEBINAR



OCTOBER

02

PRE-SHOW: **CPHI PRE-SHOW**

16

PRE-SHOW: **AAPS PHARMSCI360**

NOVEMBER

20

### SPECIAL EDITION: **PATIENT CENTRICITY**

Drug innovation will become increasingly patient-centric and personalized through the 2020s. Gene and cell therapies, for example, are proving successful in the treatment of cancers and hereditary conditions. However, the individualized nature of these treatments makes them incredibly expensive, with some costing millions of dollars per patient. As personalized patient-centric care becomes the norm, individuals will take growing control of their health data and well-being. One UK start-up has created a digital platform giving customers insights into their DNA, as well as ownership of their own health data, enabling them to make better-informed lifestyle, healthcare and treatment choices.

DECEMBER

11

### SPECIAL EDITION: **THE PATH TO A BIOLOGICS LICENSE APPLICATION**

We assess, with the help of various experts, the steps that comprise the biologics license application (BLA) process and what the US Food and Drug Administration (FDA) generally expects in this context. We will also evaluate how some biopharma players have secured a BLA and why their applications were successful.



SPECIAL EDITION



PRE-SHOW



EDITORIAL WEBINAR

# 2025

JANUARY

15

SPECIAL EDITION: **EMERGING BIOPHARMA HUBS**

Traditionally, the hubs of Boston and San Francisco in the US would be considered the epicentres of the biopharma universe, but this is evolving quickly. As the life sciences industry continues to grow at a rapid pace, more states across the US and more countries across Europe are encouraging companies to set up operation within their borders. In this newsletter, we look at how they are working to attract industry and what innovations are springing up out of these emerging hubs.

FEBRUARY

12

SPECIAL EDITION: **BIOPROCESSING 4.0**

Bioprocessing 4.0 is embodied in the tools that increase efficiency and help companies keep an edge in today’s competitive biopharma landscape. In this webinar we review approaches that use digitization to give companies the flexibility needed to adjust process parameters quickly and easily while maintaining quality and reducing time and costs. We also look at technology that improves workflows in multiple ways, shortening process development cycles and accelerating time to market, increasing product titers and yields; and boosting product quality and uniformity.

MARCH

12

SPECIAL EDITION: **TAKING BIOLOGICS THROUGH THE CLINIC**

Clinical development of biologics is a different process to that of small molecules – regulatory requirements, recruitment, clinical safety monitoring, and bioanalytics all require distinct execution. This special edition looks at the steps required to take biologics from preclinical development through to late-stage clinical trials, and the ways in which this process is being accelerated.



SPECIAL EDITION



PRE-SHOW



EDITORIAL WEBINAR